

Best Practices for Using Buprenorphine in OUD Treatment During Pregnancy

References

1. Bastian JR, Chen H, Zhang H, et al. Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy. *Am J Obstetrics and Gyn.* 2017;216(1):64.e1-64.e7. doi:<https://doi.org/10.1016/j.ajog.2016.09.095>
2. Bello JK, Xu KY, Salas J, Bedrick BS, Grucza RA. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder. *J Gen Intern Med* 2024;39(8):1342-1348. doi:<https://doi.org/10.1007/s11606-024-08689-8>
3. Caritis SN, Bastian JR, Zhang H, et al. An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy. *Am J Obstetrics and Gyn.* 2017;217(4):459.e1-459.e6. doi:<https://doi.org/10.1016/j.ajog.2017.06.029>
4. Cleary EM, Byron RK, Hinely KA, Talley AW, Costantine MM, Rood KM. Subcutaneous Buprenorphine Extended-Release Use Among Pregnant and Postpartum Women. *Obstetrics & Gynecology.* 2020;136(5):902-903. doi:<https://doi.org/10.1097/aog.0000000000004126>
5. Lofwall MR, Young JL, Hansen Z, et al. What to Expect With Pregnant or Postpartum Prescribing of Extended-Release Buprenorphine (CAM2038). *J Clinical Gyn and Obstetrics.* 2023;12(3):110-116. doi:<https://doi.org/10.14740/jcgo919>
6. Mburu M, Masese R, Knippler ET, et al. Factors associated with medications for opioid use disorder (MOUD) treatment success during the pregnancy and postpartum periods: A scoping review. *Drug Alcohol Depend.* 2024;264:112454. doi:<https://doi.org/10.1016/j.drugalcdep.2024.112454>
7. Winhusen T, Lofwall M, Jones HE, et al. Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations. *Contemporary Clinical Trials.* 2020;93:106014. doi:<https://doi.org/10.1016/j.cct.2020.106014>